A Cornell researcher, who is a leader in developing a new type of gene editing CRISPR system, and colleagues have used the new method for the first time in human cells – a major advance in the field.
The new system, called CRISPR-Cas3, can efficiently erase long stretches of DNA from a targeted site in the human genome, a capability not easily attainable in more traditional CRISPR-Cas9 systems. Though robust applications may be well in the future, the new system has the potential to seek out and erase such ectopic viruses as herpes simplex, Epstein-Barr, and hepatitis B, each of which is a major threat to public health.
“My lab spent the past ten years figuring out how CRISPR-Cas3 works. I am thrilled that my colleagues and I finally demonstrated its genome editing activity in human cells,” said Ailong Ke, professor of molecular biology and genetics and a corresponding author of a paper published April 8 in the journal Molecular Cell. “Our tools can be made to target these viruses very specifically and then erase them very efficiently. In theory, it could provide a cure for these viral diseases.”
The CRISPR-Cas3 technology also allows researchers to scan through the genome and detect non-coding genetic elements, which make up 98 percent of our genome but have not been well characterized. These elements act as regulators that control the expression of proteins in coding genes, and they’ve been found to be pivotal for cell differentiation and sex determination.
CRISPR-Cas3 could be used to efficiently screen for non-coding genetic elements and erase long sequences of DNA. Once erased, researchers may look to see what functions are missing in an organism, to determine the role of that genetic element.
Yan Zhang, assistant professor of biological chemistry at the University of Michigan, is also a corresponding author of the paper. First authors are Adam Dolan, a graduate student in Ke’s lab, and Zhonggang Hou, a research lab specialist in Zhang’s lab.
CRISPR-Cas9 systems use a bacterial RNA as a guide pairs with and recognizes a sequence of DNA. When a match is found, the guide RNA directs CRISPR-associated (Cas) proteins to that precise string of DNA. Once located, the Cas9 protein snips the target DNA at just the right place. CRISPR-Cas3 uses the same mechanism to locate a specific sequence of DNA, however, instead of snipping the DNA in half, its nuclease erases DNA continuously, for up to 100 kilobases.
For the first time, Ke, Zhang and colleagues successfully deleted sequences of up to 100 kilobases of targeted DNA in human embryonic stem cells and in another cell type called HAP1.
While CRISPR-Cas3 holds the potential for a more impactful genome-editing tool than CRISPR-Cas9, the researchers are working to control how long a section they delete. “We can’t quite define the deletion boundaries precisely, and that is a shortcoming when it comes to therapeutics,” Ke said.
The Latest on: CRISPR-Cas3
via Google News
The Latest on: CRISPR-Cas3
- Locus Biosciences initiates world's first controlled clinical trial for a CRISPR enhanced bacteriophage therapyon January 7, 2020 at 4:00 pm
RESEARCH TRIANGLE PARK, N.C., Jan. 8, 2020 /PRNewswire/ -- Locus Biosciences announced today that it has opened for enrollment a Phase 1b clinical trial evaluating LBP-EC01, a CRISPR Cas3-enhanced ...
- Locus Biosciences selected by FierceBiotech as one of its "Fierce 15" Biotech Companies of 2019on September 24, 2019 at 6:02 am
Locus is the world leader in CRISPR-engineered bacteriophage therapeutics, uniquely leveraging the powerful Type I CRISPR-Cas3 system to specifically destroy the DNA of target bacteria cells ...
- Kineticos Wins Triangle Business Journal's 2019 Life Sciences Consultant of the Yearon June 9, 2019 at 5:00 pm
Their senior consulting teams worked alongside our founders to establish the initial sets of Target Product Profiles that underpinned our CRISPR-Cas3 platform technology play. We could not speak ...
- CRISPR-Cas3 innovation holds promise for disease cures, advancing scienceon April 10, 2019 at 5:00 pm
The new system, called CRISPR-Cas3, can efficiently erase long stretches of DNA from a targeted site in the human genome, a capability not easily attainable in more traditional CRISPR-Cas9 systems.
- CRISPR-Cas3 Mechanism (image)on April 8, 2019 at 11:30 am
This is a representation of how the new technique is made possible in human cells (top box) and how it acts on DNA to create long-range deletions starting at a precise point. Disclaimer: AAAS and ...
- Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapieson January 3, 2019 at 4:00 pm
The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing ...
- Locus Biosciences Secures $5m Convertible Note for CRISPR-Cas3 Antimicrobialson July 10, 2017 at 2:30 am
RESEARCH TRIANGLE PARK, N.C., July 10, 2017 /PRNewswire/ -- Locus Biosciences Inc. today announced the closing of a $5m Convertible Note to support the development of CRISPR-Cas3 antimicrobial ...
via Bing News